US Patent 8,511,304: Scope, Claims, Expiration and Inhalation-Device Patent Landscape
US Patent 8,511,304 protects an inhaler that synchronizes multiple elongated powder-medicament carriers and releases one dose from each carrier during a single actuation. Its strongest technical coverage is directed to two peelable blister strips, coupled indexing mechanisms, simultaneous dose release, and delivery through a common inhalation outlet.
The patent is principally a device patent. It does not claim fluticasone, salmeterol, albuterol, formoterol, budesonide, or another active ingredient as a composition of matter. Its commercial relevance depends on whether a marketed inhaler uses the claimed multi-carrier architecture.
What does US Patent 8,511,304 cover?
The patent covers an inhalation device with the following core combination:
- Two or more elongated medicament carriers.
- Multiple separately accessible powder doses on each carrier.
- Different active ingredients, or different active-ingredient mixtures, on different carriers.
- A common actuation event.
- Individual indexing of each carrier.
- Mechanical coupling between the indexing systems.
- Release of one dose from each carrier per actuation.
- Simultaneous inhalation through an outlet.
The patent is directed to synchronized combination-product inhalers rather than conventional single-strip dry-powder inhalers.
A device generally must satisfy every limitation of an asserted claim to infringe that claim. A commercial inhaler using two blister strips would not necessarily infringe merely because it delivers two active ingredients. The relevant questions are whether the strips are individually indexed, whether the indexers are mutually coupled, whether one dose from each carrier is released per actuation, and whether the released powders are available through the claimed outlet arrangement.
What are the independent claims of US 8,511,304?
| Claim |
Category |
Principal scope |
| 1 |
Device |
Two elongate carriers, distinct actives, synchronized indexing, combined release and common inhalation outlet |
| 8 |
Method |
Dispensing a combination product using the claim 1 device |
| 9 |
Method |
Treating a respiratory disorder using the claim 1 device |
| 63 |
Device |
Plural carriers, coupled indexers and simultaneous release, with fewer structural limitations than claim 1 |
Claim 1 is the principal broad apparatus claim. Claim 63 is a second independent apparatus claim that removes several limitations appearing in claim 1, including the express requirements for a receiving station and a separate release element.
Claims 8 and 9 convert the apparatus concept into method claims. Claims 10 and 11 limit the respiratory disease to asthma and COPD.
How broad is claim 1?
Claim 1 requires more than two drug reservoirs. The claimed device must include:
- Two elongated medicament carriers;
- Multiple distinct powder dose portions on each carrier;
- Different actives or active mixtures on the respective carriers;
- A dispensing mechanism acting on both carriers together;
- An indexer for each carrier;
- Mutual coupling of the indexers;
- Release of one dose from each carrier per actuation; and
- An outlet permitting simultaneous inhalation.
The requirement that the indexers be “mutually coupled” is a central limitation. A device in which each strip advances independently, without mechanical or functional coupling, presents a stronger non-infringement position against claim 1.
The coupling mechanism is not limited in claim 1 to gears. Claim 62 narrows the claim to coupling through a gear train, implying that claim 1 can encompass other forms of coupling.
How broad is claim 63?
Claim 63 is structurally important because it recites:
- Plural elongated carriers;
- Different active ingredients or active mixtures;
- An actuator;
- A dispensing mechanism acting on each carrier;
- An indexer for each carrier;
- Mutually coupled indexers; and
- An outlet for simultaneous inhalation.
Unlike claim 1, claim 63 does not expressly require the “at least one receiving station” and “release” sub-elements in the same detailed form. It instead requires a dispensing mechanism adapted to release a dose from each carrier.
A product assessment should begin with claims 1 and 63 because they define the principal device-level coverage. Claim 63 may be more adaptable to designs that use a different opening or dose-release architecture.
What formulations and drug combinations are protected?
The patent does not claim a specific pharmaceutical composition in the conventional chemical sense. It claims the device and delivery method when used with specified classes or combinations of inhaled medicines.
Relevant dependent claims include:
| Claims |
Technical limitation |
| 35-37 |
Single active component per dose; anti-inflammatory, bronchodilator or anticholinergic; fluticasone ester |
| 53 |
Albuterol, salmeterol, fluticasone propionate, formoterol, budesonide or beclomethasone dipropionate, including salts and solvates |
| 54-55 |
One carrier with a bronchodilator and the other with an anti-inflammatory; beta-agonist and steroid combinations |
| 56-59 |
One or both carriers containing multiple active components |
| 60-61 |
Treatment method using the specified active classes and a fluticasone ester |
| 70-74 |
Equivalent active-ingredient limitations under claim 63 |
The patent therefore has relevance to combination respiratory therapies such as:
- Inhaled corticosteroid plus long-acting beta agonist;
- Bronchodilator plus anti-inflammatory;
- Beta agonist plus steroid;
- Single-agent carrier combined with a multi-active carrier; and
- Products containing anticholinergic agents.
The active-ingredient references are dependent limitations. They do not mean that every inhaler containing fluticasone or salmeterol falls within the patent.
What blister-strip and mechanical features are protected?
Claims 4, 5 and 12-30 contain the most detailed mechanical coverage.
Peelable blister strips
Claim 12 requires:
- Blister strips containing multiple pockets;
- Base and lid sheets;
- Peelable separation of the sheets;
- An opening station;
- At least one peeler;
- Indexing of the pockets on each strip; and
- Access to the opened pockets through the outlet.
Claims 13 and 14 cover either a common opening station or separate opening stations. Claims 18 and 19 distinguish between a common peeler and distinct peelers.
Lid-driver and tension-control mechanisms
Claims 20-28 cover specific strip-opening hardware, including:
- A lid driver that pulls the lid sheet from the base sheet;
- A wheel that winds the lid sheet;
- A progressively collapsing winding structure intended to maintain an approximately constant winding diameter;
- A clutch controlling the peeled strip length;
- Tension-compensation systems;
- Flexible members and variable-length springs;
- Torsion springs; and
- Separate paths for the peeled lid and base sheets.
These claims are narrower than claims 1 and 63 but can be significant against a device that adopts the same strip-peeling architecture.
Indexing and carrier geometry
Claims 29 and 66-67 cover rotatable index wheels with recesses that engage blister pockets. Claims 31-34 cover continuous-loop carriers, including looped base sheets and looped or strip-form lid sheets.
Claims 38-52 cover the spatial and dose-layout options:
- Strip or tape carriers;
- Blister-pack carriers;
- Peelable blister strips;
- Equivalent or non-equivalent doses;
- Uniform spacing;
- Progressively increasing spacing;
- Side-by-side configuration;
- Double-decker configuration; and
- Back-to-back configuration.
The claims are therefore designed to capture both the functional synchronization concept and multiple physical implementations.
How does the patent protect simultaneous combination dosing?
The patent’s central commercial concept is synchronized co-dosing. Each actuation is intended to produce one dose from each carrier, with both doses available for inhalation during the same respiratory maneuver.
This creates several potential infringement pathways:
- A device may infringe even if the active ingredients are stored separately.
- The two powders need not be pre-mixed in a single blister pocket.
- The device can use separate carrier chambers or a common receiving station.
- A common outlet can deliver both powders.
- Claim 7 specifically covers an outlet shaped to encourage mixing.
- A product can use one carrier with a single active and another with multiple actives under claims 56-59.
The patent does not require that the powders be chemically blended before loading. It focuses on coordinated mechanical release and simultaneous access by the patient.
What patent claims cover the carriers and dose spacing?
Claims 38-52 create a broad set of alternative carrier configurations.
A carrier may be:
- A strip;
- A tape;
- A blister pack;
- A peelable blister strip; or
- A continuous loop.
The dose portions may be equivalent or non-equivalent in size. Their spacing may be uniform or progressively increasing. This matters because an inhaler can compensate for different carrier lengths, different pocket spacing, or different dose schedules while maintaining synchronized delivery.
Claims 43 and 44 also cover specific laminate structures.
The lid sheet may contain:
- Paper;
- Polyester;
- Aluminum foil; and
- Heat-seal lacquer.
The base sheet may contain:
- Oriented polyamide;
- Aluminum foil; and
- A polymeric layer.
These claims are manufacturing-oriented and narrower than the core synchronization claims. They may be relevant where a competitor uses substantially the same multilayer barrier-film construction.
When does US Patent 8,511,304 lose exclusivity?
The patent issued on August 20, 2013. Its earliest priority is in the 2004 period, and the ordinary 20-year patent term is therefore projected to end in December 2025, subject to any applicable patent-term adjustment or other term calculation under the official USPTO record.
| Event |
Date or period |
| Earliest priority period |
December 2004 |
| U.S. patent application |
Before issuance in 2013 |
| Patent grant |
August 20, 2013 |
| Projected ordinary expiration |
December 2025 |
| Patent-term extension |
No drug-specific PTE is apparent from the device-claim structure |
| Patent-term adjustment |
Must be taken from the USPTO patent record |
Because this is a device patent, Hatch-Waxman patent-term extension is materially less likely than for an approved active ingredient or drug product patent. The patent’s expiration should be calculated from the official patent-term data rather than the grant date.
What is the Orange Book status of US 8,511,304?
US 8,511,304 is not a conventional Orange Book drug-substance patent. Its claims are directed primarily to an inhalation device, dispensing mechanism, carrier arrangement and treatment method.
Orange Book listing generally depends on whether a patent claims an approved drug substance, drug product, formulation or method of use associated with an approved NDA. A device patent may be relevant to an NDA product, but device-only claims are not automatically listed.
The patent is therefore better analyzed as a device and combination-product patent than as an Orange Book composition-of-matter patent. Its presence or absence in an NDA patent listing should be checked against the relevant FDA product entry and NDA-specific patent submission records. The patent number alone does not establish Orange Book listing status.
Are Paragraph IV challenges relevant?
A Paragraph IV certification is principally directed to an Orange Book-listed patent. If US 8,511,304 is not listed for a particular approved drug product, a generic applicant would not ordinarily use a Paragraph IV certification against this patent through the standard Orange Book route.
The more relevant litigation theories would be:
- Direct patent infringement involving a competing inhaler;
- Declaratory judgment of non-infringement or invalidity;
- Inter partes review or post-grant validity proceedings;
- Patent exhaustion;
- Contributory or induced infringement claims involving device supply; and
- Contract or license disputes involving inhaler platforms.
A generic dry-powder inhaler using one carrier would generally face a lower risk under these claims. A competing dual-strip inhaler with mechanically coupled indexing presents a materially higher risk.
Which companies and products are commercially relevant?
The technology is most relevant to companies developing multi-active dry-powder inhalers with separate dose carriers. The principal commercial comparison is with GSK’s Ellipta platform and related inhaled respiratory products, including products combining an inhaled corticosteroid with a bronchodilator or combining multiple bronchodilators.
Relevant product categories include:
| Product architecture |
Relevance to US 8,511,304 |
| Single blister strip DPI |
Usually outside the principal two-carrier claims |
| Two separately indexed strips |
Directly relevant |
| Two strips with mechanically coupled gears |
Strongest technical overlap |
| Two actives pre-mixed in one pocket |
May avoid separate-carrier limitations |
| Capsule-based DPI |
Generally outside the claimed blister-strip embodiments, but claim 1 is not limited to blisters |
| Multi-dose reservoir inhaler |
Depends on whether it has separate elongated carriers and coupled indexing |
| Pressurized metered-dose inhaler |
Usually outside the claimed powder-carrier architecture |
The patent’s commercial importance is greatest where an inhaler uses separate foil blister strips because of formulation, stability or dose-separation requirements.
How strong is the patent estate?
The patent has meaningful claim breadth at the architecture level but is exposed to several validity and claim-construction issues.
Strengths
- Two independent device claims, including claim 63 with a different limitation structure.
- Broad coverage of synchronized indexing.
- Coverage of different carrier geometries and layouts.
- Dependent claims directed to peelable blister strips and practical opening mechanisms.
- Coverage of both single-active and multi-active carrier arrangements.
- Treatment-method claims for asthma and COPD.
- Claims directed to gear coupling, which can map directly onto mechanically synchronized designs.
Vulnerabilities
- The core concept of combining separate inhaled medicines may have substantial prior-art exposure.
- Claims require a specific relationship between multiple carriers, indexers and release events.
- Dependent claims directed to particular film laminates, springs, clutches and peelers are comparatively narrow.
- Method claims may face divided-infringement and patient-use enforcement issues.
- Claims 37 and 61 refer to “fluticasone ester,” a category broader than a single approved fluticasone product but potentially subject to written-description and claim-construction disputes.
- Several dependent claims appear to contain drafting anomalies in their dependency references, including claims 66-69. Their enforceability would depend on the issued claim text, prosecution history and any applicable correction.
Overall, the strongest practical claims are likely claims 1 and 63, followed by claims 12, 29, 54-59, 64-69 and 70-74 when a competing product uses the corresponding physical architecture and respiratory drug combination.
What manufacturing and intellectual-property barriers exist?
A competitor must solve more than the pharmacology. The principal engineering barriers include:
- Maintaining synchronized indexing across carriers;
- Preventing dose misalignment after partial actuation;
- Peeling blister lids without powder loss;
- Controlling peel tension;
- Managing discarded lid and base materials;
- Maintaining moisture and oxygen barrier performance;
- Preventing cross-contamination between powders;
- Delivering both powders through one outlet;
- Preserving dose uniformity over the product shelf life; and
- Coordinating device assembly with two separately filled carrier systems.
The patent targets several of these barriers. Separate patents or know-how may cover blister-film materials, powder formulations, dose metering, airflow resistance, mouthpiece design, manufacturing equipment and product-specific regulatory controls.
What generic launch risks exist?
A generic or follow-on manufacturer faces four principal risk categories.
Device infringement risk
The highest risk occurs where the product has two elongated blister carriers with coupled indexing and simultaneous dose release.
Regulatory substitution risk
An inhaler using a different device may not qualify as therapeutically or pharmaceutically equivalent to the reference product without additional FDA analysis. Device differences can affect dose delivery, airflow resistance, patient handling and clinical performance.
Formulation and stability risk
Separate carriers may be used to prevent chemical or physical incompatibility between actives. A generic manufacturer may not be able to combine the actives into one carrier without changing product performance.
Manufacturing risk
Dual-strip filling, sealing, indexing and assembly increase capital requirements and quality-control complexity. These barriers can delay market entry even after patent expiry.
What litigation and licensing issues should be reviewed?
The relevant diligence record should include:
- The USPTO patent file and continuation applications;
- Patent-term adjustment data;
- Patent assignments and security interests;
- Cited and citing references;
- Federal court litigation involving the patent family;
- PTAB proceedings;
- FDA Orange Book entries for products using the relevant inhaler platform;
- License agreements involving the device developer and respiratory-product sponsor; and
- Product-specific patents covering formulations, doses and methods of use.
The commercial history of multi-strip inhalers has involved collaboration between inhaler-technology developers and branded respiratory companies. A product license does not establish that every patent in a developer’s portfolio covers the licensed product. Claim charts and license schedules are required to connect US 8,511,304 to a specific commercial inhaler.
Key Takeaways
- US 8,511,304 is a multi-carrier inhalation-device patent, not a traditional active-ingredient patent.
- Its core concept is synchronized release of separate powder doses from multiple elongated carriers.
- Claims 1 and 63 provide the principal device coverage.
- Claims 12-30 focus on peelable blister strips, opening stations, peelers, lid drivers and tension compensation.
- Claims 54-59 and 70-74 address bronchodilator, steroid and multi-active combinations.
- A dual-strip inhaler with mutually coupled indexing presents the highest technical overlap.
- A single-strip, reservoir, capsule or pre-mixed-pocket inhaler may have stronger design-around arguments, depending on its detailed mechanics.
- The ordinary patent term is projected to end in December 2025, subject to USPTO patent-term adjustment.
- Orange Book and Paragraph IV relevance is limited because the patent claims an inhalation device and treatment methods rather than a conventional drug substance.
- The principal commercial exposure is in combination dry-powder inhalers using separate blister carriers, including architectures associated with branded respiratory platforms such as Ellipta.
- Patent expiry does not remove formulation, device, manufacturing, regulatory or separate patent barriers.
FAQs
Does US 8,511,304 cover Ellipta inhalers?
It may be technically relevant to an Ellipta-type inhaler that uses separate blister carriers and synchronized dose delivery, but infringement cannot be determined from product branding alone. The exact device construction, patent-family licensing and claim interpretation control.
Can a competitor avoid the patent by placing both drugs in one blister pocket?
Potentially. A single-pocket, pre-mixed formulation may avoid the requirement for distinct active-containing carriers. Other limitations, including the carrier and indexing language of the asserted claim, must still be analyzed.
Does the patent cover capsule inhalers?
The broadest claims are not expressly limited to blister strips, but many dependent claims are. A capsule device would need to be compared against the elongated-carrier, multiple-dose, coupled-indexer and simultaneous-release limitations.
Does patent expiration allow immediate generic substitution?
No. Expiration removes the patent exclusion right but does not guarantee FDA approval, therapeutic equivalence, substitutability or manufacturing readiness.
Are the fluticasone claims composition-of-matter claims?
No. Claims 37 and 61 use fluticasone ester as an active-ingredient limitation in device or treatment claims. They do not claim fluticasone as a standalone chemical composition.
References
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,511,304, Inhalation device.
- United States Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- United States Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources.
- GlaxoSmithKline plc. (n.d.). Annual reports and respiratory medicines product information.
